Bedrijfsoverzicht
Universe Pharmaceuticals INC is a specialized entity within the healthcare sector, specifically operating in the industry of drug manufacturers focused on specialty and generic products. The company's core business involves the manufacturing, marketing, distribution, and sale of traditional Chinese medicine derivative products primarily for the Chinese market. These products are specifically formulated to address the treatment and relief of common chronic health conditions prevalent among the elderly population. Operating with a workforce of 216 employees, the company maintains a market capitalization of $1.72 million and reported annual revenue of $17.86 million over the trailing twelve months. These financial figures indicate that Universe Pharmaceuticals functions as a small-cap enterprise with a relatively modest revenue base compared to large-scale pharmaceutical conglomerates, reflecting its niche positioning in the specialized generic drug market.
Financiële gezondheid
The company reported a revenue of $17.86 million for the trailing twelve months, yet this generated a net income of -$3,672,055 and an EBITDA of -$2,398,488. The significant disparity between the positive revenue figure and the substantial negative net income reveals a cost structure where operating expenses and overhead costs far exceed gross profits, resulting in a loss situation. Free cash flow stands at -$10,243,885, which indicates that the company is currently burning cash rather than generating liquidity from its operations. This negative cash flow suggests a reliance on existing cash reserves or external financing to fund ongoing operations and strategic initiatives. The gross margin is recorded at 35.3%, while the operating margin is -6.8% and the profit margin is -20.6%, highlighting that while the cost of goods sold is managed reasonably well, other operational inefficiencies or high selling, general, and administrative expenses are eroding profitability. The company holds $33.59 million in cash against $9.26 million in debt, creating a net cash position that provides a buffer despite the negative earnings. The debt-to-equity ratio of 16.49% further underscores a conservative leverage profile, as the company carries significantly less debt relative to its equity base. Liquidity is robust with a current ratio of 4.07, indicating that the firm possesses more than four times the current assets necessary to cover its short-term liabilities without immediate distress. Return on equity is -7.2% and return on assets is -2.7%, metrics that demonstrate the company is currently destroying shareholder value and utilizing its asset base to generate negative returns in the current reporting period.
Waarderingsbeoordeling
Both the trailing P/E ratio and the forward P/E ratio are listed as N/A due to the company's lack of positive earnings, meaning traditional earnings-based valuation multiples cannot be applied to assess expected earnings trajectory. The price-to-book ratio is 0.03, which indicates that the market values the company at a fraction of its tangible book value, suggesting a deep discount or that the market assigns low value to its intangible assets and future prospects. The price-to-sales ratio is 0.10 and the EV/EBITDA multiple is 9.43, providing alternative valuation contexts where the stock trades at a very low multiple of its revenue, reflecting market skepticism regarding its ability to convert sales into sustainable profits. The 52-week high for the stock is $11.00 and the 52-week low is $2.00, placing the current market price in a wide trading range that suggests high volatility and significant potential for price discovery. Given the lack of earnings, the valuation is heavily dependent on revenue growth potential and the strategic value of its traditional Chinese medicine portfolio rather than current profitability. The beta value of 1.48 indicates that the stock price is significantly more volatile than the broader market, moving with greater intensity during periods of market stress or gain.
Growth & Income
Revenue growth year-over-year is -14.1%, while earnings growth is N/A, reflecting the current unprofitable state of the business. The contraction in revenue suggests a challenging operating environment or a loss of market share within the specific niche of traditional Chinese medicine derivatives. Since the company is currently unprofitable, it does not pay dividends, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%. Consequently, the company reinvests its limited cash flow and existing capital reserves into growth initiatives rather than distributing income to shareholders. The overall growth and income profile characterizes Universe Pharmaceuticals as a high-risk, non-income investment that relies entirely on future operational improvements to reverse the negative revenue trend and achieve profitability.